Heart help for failing kidneys: old drug, new hope?
NCT ID NCT06182839
Summary
This study is testing if a diabetes medication called canagliflozin can improve heart structure and function in people with advanced kidney disease, including those on dialysis. About 92 participants will take either the drug or a placebo for one year, with doctors using heart MRI scans to see if the drug reduces harmful heart thickening. The main goal is to see if this treatment can help control heart complications, a major risk for people with severe kidney problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESRD, CKD STAGE 4, CKD STAGE 5 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Center
RECRUITINGMontreal, Quebec, Canada
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.